Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Merck
AstraZeneca
McKinsey
Express Scripts

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Ertapenem sodium - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for ertapenem sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme Corp.Phase 4
Albany College of Pharmacy and Health SciencesPhase 4
Merck Sharp & Dohme Corp.Phase 3

See all ertapenem sodium clinical trials

Recent Litigation for ertapenem sodium

Identify potential future generic entrants

District Court Litigation
Case NameDate
Merck Sharp & Dohme Corp. v. Hospira, Inc.2016-10-26
Merck Sharp & Dohme Corp. v. Savior Lifetec Corp.2015-08-21
Merck Sharp & Dohme Corp. v. Hospira Inc.

See all ertapenem sodium litigation

Pharmacology for ertapenem sodium
Synonyms for ertapenem sodium
(4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium
(4R,5S,6S)-3-[[(3S,5S)-5-[[(3-Carboxyphenyl)amino]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid Sodium Salt
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, disodium salt (4R,5S,6S)-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, monosodium salt, (4R,5S,6S)-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, monosodium salt, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-monosodium salt,(4R-(3(3S*,5S*), 4alpha,5beta,6beta(R*)))
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, disodium salt, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylicacid,3-(((3S,5S)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-,monosodiumsalt,(4R,5S,6S)-
153773-82-1
153832-38-3
153832-46-3 (acid)
202467-69-4 (acid)
2T90KE67L0
A809465
AC-1633
AC1L44OO
AK142836
AKOS016014925
AKOS025401431
AKOS025402550
AN-14741
AN-14742
BC656994
C22H24N3NaO7S
CHEBI:60070
CHEMBL1232
CS-8020
D04049
disodium (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxylatophenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
Ertapenem disodium
Ertapenem Disodium (85%)
ertapenem monosodium
Ertapenem monosodium, Antibiotic for Culture Media Use Only
Ertapenem sodium (USAN)
Ertapenem sodium [USAN]
Ertapenem sodium salt
FT-0667958
FT-0697739
HY-13625
Invanz
Invanz (TN)
J-009050
KMVRATCHVMUJHM-SHZCTIMHSA-L
L 749
L 749345
L 749345, MK 826
L-749345
LS-181819
MK 0826
MK 826
MK-0826
MK-826
MolPort-019-992-343
MolPort-023-299-459
MolPort-027-947-972
P5HEA33D9R
Q-201065
SB18986
SC-82925
SCHEMBL102761
sodium (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxylatophenyl)carbamoyl]pyrrolidinium-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
sodium (4R,5S,6S)-3-({(3S,5S)-5-[(m-carboxylatophenyl)carbamoyl]pyrrolidinium-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
sodium (4R,5S,6S)-3-({(3S,5S)-5-[(m-carboxyphenyl)carbamoyl]-3-pyrrolidinyl}thio)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
sodium 3-((2S,4S)-4-(((4R,5S,6S)-2-carboxy-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl)thio)pyrrolidine-2-carboxamido)benzoate
sodium 3-[[(2S,4S)-4-[[(4R,5S,6S)-2-carboxy-4-methyl-6-[(1R)-1-oxidanylethyl]-7-oxidanylidene-1-azabicyclo[3.2.0]hept-2-en-3-yl]sulfanyl]pyrrolidin-2-yl]carbonylamino]benzoate
Sodium 3-[[(2S,4S)-4-[[(4R,5S,6S)-2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]sulfanyl]pyrrolidine-2-carbonyl]amino]benzoate
sodium 3-[[(2S,4S)-4-[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]sulfanyl]pyrrolidine-2-carbonyl]amino]benzoate
sodium 3-[[[(2S,4S)-4-[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-2-pyrrolidinyl]-oxomethyl]amino]benzoate
ST2406824
UNII-2T90KE67L0
UNII-P5HEA33D9R
X8147
ZD-443 sodium
ZD-4433
ZXNAQFZBWUNWJM-HRXMHBOMSA-M
Paragraph IV (Patent) Challenges for ERTAPENEM SODIUM
Tradename Dosage Ingredient NDA Submissiondate
INVANZ INJECTABLE;INTRAMUSCULAR, INTRAVENOUS ertapenem sodium 021337 2012-12-21

US Patents and Regulatory Information for ertapenem sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Savior Lifetec Corp ERTAPENEM SODIUM ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 207647-001 Mar 19, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Aurobindo Pharma Ltd ERTAPENEM SODIUM ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 209133-001 Jun 25, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
Acs Dobfar Spa ERTAPENEM SODIUM ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 208790-001 Apr 16, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ertapenem sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001   Start Trial   Start Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001   Start Trial   Start Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001   Start Trial   Start Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Colorcon
Merck
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.